{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:28:49Z","timestamp":1787246929349,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01817-8","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:17:44Z","timestamp":1781097464000},"page":"3733-3755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric Melanoma: Emerging Therapies and Ongoing Clinical Trials"],"prefix":"10.1007","volume":"16","author":[{"given":"Pablo","family":"Balado-Sim\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hern\u00e1ndez-Santacana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mansilla-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"1817_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clindermatol.2025.01.010","volume":"43","author":"P McMullan","year":"2025","unstructured":"McMullan P, Grant-Kels JM. Childhood and adolescent melanoma: an update. Clin Dermatol. 2025;43:16\u201323.","journal-title":"Clin Dermatol"},{"key":"1817_CR2","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/jdv.19220","volume":"37","author":"R Pampena","year":"2023","unstructured":"Pampena R, Piccolo V, Muscianese M, et\u00a0al. Melanoma in children: a systematic review and individual patient meta-analysis. J Eur Acad Dermatol Venereol. 2023;37:1758\u201376.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1817_CR3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jpeds.2015.02.050","volume":"166","author":"LB Campbell","year":"2015","unstructured":"Campbell LB, Kreicher KL, Gittleman HR, et\u00a0al. Melanoma incidence in children and adolescents: decreasing trends in the United States. J Pediatr. 2015;166:1505\u201313.","journal-title":"J Pediatr"},{"key":"1817_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S2352-4642(19)30116-6","volume":"3","author":"EA Merkel","year":"2019","unstructured":"Merkel EA, Mohan LS, Shi K, et\u00a0al. Paediatric melanoma: clinical update, genetic basis, and advances in diagnosis. Lancet Child Adolesc Health. 2019;3:646\u201354.","journal-title":"Lancet Child Adolesc Health"},{"key":"1817_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jaad.2017.09.065","volume":"78","author":"C Carrera","year":"2018","unstructured":"Carrera C, Scope A, Dusza SW, et\u00a0al. Clinical and dermoscopic characterization of pediatric and adolescent melanomas: Multicenter study of 52 cases. J Am Acad Dermatol. 2018;78:278\u201388.","journal-title":"J Am Acad Dermatol"},{"key":"1817_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2012.12.953","volume":"68","author":"KM Cordoro","year":"2013","unstructured":"Cordoro KM, Gupta D, Frieden IJ, et\u00a0al. Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol. 2013;68:913\u201325.","journal-title":"J Am Acad Dermatol"},{"key":"1817_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.soc.2020.11.005","volume":"30","author":"JH Aldrink","year":"2021","unstructured":"Aldrink JH, Polites SF, Austin M. Pediatric melanoma-diagnosis, management, and anticipated outcomes. Surg Oncol Clin N Am. 2021;30:373\u201388.","journal-title":"Surg Oncol Clin N Am"},{"key":"1817_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.24.01154","volume":"43","author":"MR Sargen","year":"2025","unstructured":"Sargen MR, Barnhill RL, Elder DE, et\u00a0al. Evaluation and surgical management of pediatric cutaneous melanoma and atypical Spitz and non-Spitz melanocytic tumors (melanocytomas): a report from children\u2019s oncology group. J Clin Oncol. 2025;43:1157\u201367.","journal-title":"J Clin Oncol"},{"key":"1817_CR9","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1002\/cncr.33750","volume":"127","author":"AS Pappo","year":"2021","unstructured":"Pappo AS, McPherson V, Pan H, et\u00a0al. A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions. Cancer. 2021;127:3825\u201331.","journal-title":"Cancer"},{"key":"1817_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA\u2014a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.","journal-title":"Res Integr Peer Rev"},{"key":"1817_CR11","volume-title":"AJCC cancer staging manual","year":"2017","unstructured":"Amin MB, Edge S, Greene F, et\u00a0al. editors. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.","edition":"8th ed"},{"key":"1817_CR12","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, et\u00a0al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, Phase 3 trial. Lancet. 2022;399:1718\u201329.","journal-title":"Lancet"},{"key":"1817_CR13","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, et\u00a0al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, Phase 3 CheckMate 76K trial. Nat Med. 2023;29:2835\u201343.","journal-title":"Nat Med"},{"key":"1817_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114305","volume":"211","author":"M Mandal\u00e0","year":"2024","unstructured":"Mandal\u00e0 M, Ferrari A, Brecht IB, et\u00a0al. Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study). Eur J Cancer. 2024;211:114305.","journal-title":"Eur J Cancer"},{"key":"1817_CR15","doi-asserted-by":"crossref","unstructured":"Du Y, Qi Z, Liang X, et\u00a0al. pembrolizumab versus high-dose interferon-\u03b12b as adjuvant therapy for pediatric melanoma: a retrospective study. Dermatol Pract Concept 2024;e2024026\u2013e2024026.","DOI":"10.5826\/dpc.1401a26"},{"key":"1817_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger B, Kang HJ, Yalon-Oren M, et\u00a0al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, Phase 1\u20132 trial. Lancet Oncol. 2020;21:121\u201333.","journal-title":"Lancet Oncol"},{"key":"1817_CR17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/cancers16050968","volume":"16","author":"A Marja\u0144ska","year":"2024","unstructured":"Marja\u0144ska A, Pawi\u0144ska-W\u0105sikowska K, Wieczorek A, et\u00a0al. Anti-PD-1 therapy in advanced pediatric malignancies in nationwide study: good outcome in skin melanoma and Hodgkin lymphoma. Cancers. 2024;16:968.","journal-title":"Cancers"},{"key":"1817_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/08880018.2024.2350455","volume":"41","author":"A Bowden","year":"2024","unstructured":"Bowden A, Zambito J, El-Feghaly J, Andolina JR. Adjuvant immune checkpoint inhibitor therapy may benefit pediatric patients with stage III melanoma and sentinel lymph node positivity: a case series. Pediatr Hematol Oncol. 2024;41:389\u201398.","journal-title":"Pediatr Hematol Oncol"},{"key":"1817_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, et\u00a0al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, Phase 1\u20132 trial. Lancet Oncol. 2020;21:541\u201350.","journal-title":"Lancet Oncol"},{"key":"1817_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ejca.2017.09.032","volume":"86","author":"B Geoerger","year":"2017","unstructured":"Geoerger B, Bergeron C, Gore L, et\u00a0al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017;86:358\u201363.","journal-title":"Eur J Cancer"},{"key":"1817_CR21","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","volume":"22","author":"MS Merchant","year":"2016","unstructured":"Merchant MS, Wright M, Baird K, et\u00a0al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22:1364\u201370.","journal-title":"Clin Cancer Res"},{"key":"1817_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31644","volume":"72","author":"S Chiaravalli","year":"2025","unstructured":"Chiaravalli S, Indini A, Del Vecchio M, et\u00a0al. Dabrafenib and trametinib for the treatment of pediatric and adolescent melanoma: single center experience data from Italian compassionate use. Pediatr Blood Cancer. 2025;72:e31644.","journal-title":"Pediatr Blood Cancer"},{"key":"1817_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26947","volume":"65","author":"JC Chisholm","year":"2018","unstructured":"Chisholm JC, Suvada J, Dunkel IJ, et\u00a0al. BRIM-P: A Phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer. 2018;65:e26947.","journal-title":"Pediatr Blood Cancer"},{"key":"1817_CR24","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/cncr.20860","volume":"103","author":"F Navid","year":"2005","unstructured":"Navid F, Furman WL, Fleming M, et\u00a0al. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer. 2005;103:780\u20137.","journal-title":"Cancer"},{"key":"1817_CR25","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.21873\/anticanres.13547","volume":"39","author":"A Marjanska","year":"2019","unstructured":"Marjanska A, Galazka P, Marjanski M, et\u00a0al. Efficacy and toxicity of pembrolizumab in pediatric metastatic recurrent melanoma. Anticancer Res. 2019;39:3945\u20137.","journal-title":"Anticancer Res"},{"key":"1817_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/bjd.16270","volume":"178","author":"G Salomon","year":"2018","unstructured":"Salomon G, Maza A, Boulinguez S, et\u00a0al. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. Br J Dermatol. 2018;178:1199\u2013203.","journal-title":"Br J Dermatol"},{"key":"1817_CR27","doi-asserted-by":"publisher","first-page":"E370","DOI":"10.1002\/dc.24817","volume":"49","author":"S Lajara","year":"2021","unstructured":"Lajara S, Landau M. Metastatic malignant melanoma mimicking a salivary gland basaloid neoplasm after treatment with nivolumab. Diagn Cytopathol. 2021;49:E370-3.","journal-title":"Diagn Cytopathol"},{"key":"1817_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/pde.15097","volume":"40","author":"KA Mueller","year":"2023","unstructured":"Mueller KA, Cordisco MR, Scott GA, Plovanich ME. A case of severe nivolumab-induced lichen planus pemphigoides in a child with metastatic spitzoid melanoma. Pediatr Dermatol. 2023;40:154\u20136.","journal-title":"Pediatr Dermatol"},{"key":"1817_CR29","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3748\/wjg.v26.i16.1971","volume":"26","author":"HH Vindum","year":"2020","unstructured":"Vindum HH, Agnholt JS, Nielsen AWM, et\u00a0al. Severe steroid refractory gastritis induced by nivolumab: a case report. W J Gastroenterol. 2020;26:1971\u20138.","journal-title":"W J Gastroenterol"},{"key":"1817_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/pde.14732","volume":"38","author":"M Roberts","year":"2021","unstructured":"Roberts M, Moxham JP, Gregory A, et\u00a0al. Ulcerated amelanotic melanoma of the ear in an 11 year old with Fitzpatrick VI skin type: a case report. Pediatr Dermatol. 2021;38:106\u20139.","journal-title":"Pediatr Dermatol"},{"key":"1817_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26702","volume":"65","author":"AC Weyand","year":"2018","unstructured":"Weyand AC, Mody RJ, Rabah RM, Opipari VP. PD-1 inhibition in congenital pigment synthesizing metastatic melanoma. Pediatr Blood Cancer. 2018;65:e26702.","journal-title":"Pediatr Blood Cancer"},{"key":"1817_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001680","volume":"43","author":"V Mitre","year":"2021","unstructured":"Mitre V, Heym K, Clark GD, Venkatramani R. Neurocutaneous melanocytosis and leptomeningeal melanoma. J Pediatr Hematol Oncol. 2021;43:e195.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1817_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/pde.14940","volume":"39","author":"N Aljundi","year":"2022","unstructured":"Aljundi N, Utz Petry S, Moossavi M, Daveluy S. Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms following nivolumab and ipilimumab in a pediatric patient with melanoma. Pediatr Dermatol. 2022;39:486\u20137.","journal-title":"Pediatr Dermatol"},{"key":"1817_CR34","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/CMR.0000000000000593","volume":"29","author":"J Mangana","year":"2019","unstructured":"Mangana J, Dimitriou F, Braun R, et\u00a0al. Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma. Melanoma Res. 2019;29:648\u201354.","journal-title":"Melanoma Res"},{"key":"1817_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","volume":"42","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Larribere L, Pan L, et\u00a0al. Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imag. 2015;42:386\u201396.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"1817_CR36","doi-asserted-by":"publisher","first-page":"9639585","DOI":"10.1155\/2016\/9639585","volume":"2016","author":"M Sioud","year":"2016","unstructured":"Sioud M, Nyakas M, S\u00e6b\u00f8e-Larssen S, et\u00a0al. Diversification of antitumour immunity in a patient with metastatic melanoma treated with ipilimumab and an IDO-silenced dendritic cell vaccine. Case Rep Med. 2016;2016:9639585.","journal-title":"Case Rep Med"},{"key":"1817_CR37","doi-asserted-by":"publisher","first-page":"456","DOI":"10.5507\/bp.2016.018","volume":"160","author":"J Volejnikova","year":"2016","unstructured":"Volejnikova J, Bajciova V, Sulovska L, et\u00a0al. Bone marrow metastasis of malignant melanoma in childhood arising within a congenital melanocytic nevus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160:456\u201360.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"1817_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.660172","author":"AL Ryan","year":"2021","unstructured":"Ryan AL, Burns C, Gupta AK, et\u00a0al. Malignant melanoma in children and adolescents treated in pediatric oncology centers: an Australian and New Zealand Children\u2019s Oncology Group (ANZCHOG) study. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.660172.","journal-title":"Front Oncol"},{"key":"1817_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/20450885.2024.2382075","volume":"11","author":"C Vyas","year":"2024","unstructured":"Vyas C, Moshyk A, Fusaro G, et\u00a0al. Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature review. Melanoma Manag. 2024;11:2382075.","journal-title":"Melanoma Manag"},{"key":"1817_CR40","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jpedsurg.2019.09.036","volume":"55","author":"JH Aldrink","year":"2020","unstructured":"Aldrink JH, Polites S, Lautz TB, et\u00a0al. What\u2019s new in pediatric melanoma: an update from the APSA cancer committee. J Pediatr Surg. 2020;55:1714\u201321.","journal-title":"J Pediatr Surg"},{"key":"1817_CR41","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/bjd.15301","volume":"176","author":"VA Kinsler","year":"2017","unstructured":"Kinsler VA, O\u2019Hare P, Bulstrode N, et\u00a0al. Melanoma in congenital melanocytic naevi. Br J Dermatol. 2017;176:1131\u201343.","journal-title":"Br J Dermatol"},{"key":"1817_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1158\/2159-8290.CD-12-0464","volume":"3","author":"M Pedersen","year":"2013","unstructured":"Pedersen M, K\u00fcsters-Vandevelde HVN, Viros A, et\u00a0al. Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov. 2013;3:458\u201369.","journal-title":"Cancer Discov"},{"key":"1817_CR43","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MOP.0000000000000917","volume":"32","author":"D Moustafa","year":"2020","unstructured":"Moustafa D, Neale H, Hawryluk EB. Trends in pediatric skin cancer. Curr Opin Pediatr. 2020;32:516\u201323.","journal-title":"Curr Opin Pediatr"},{"key":"1817_CR44","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00520-025-10092-w","volume":"33","author":"N Ahmad","year":"2025","unstructured":"Ahmad N, Moore R, He J, et\u00a0al. Patient-reported quality of life in adolescents and young adults with melanoma. Support Care Cancer. 2025;33:1047.","journal-title":"Support Care Cancer"},{"key":"1817_CR45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s11764-023-01508-9","volume":"19","author":"C Paterson","year":"2025","unstructured":"Paterson C, Kavanagh PS, Bacon R, et\u00a0al. To understand the experiences, needs, and preferences for supportive care, among children and adolescents (0\u201319 years) diagnosed with cancer: a systematic review of qualitative studies. J Cancer Surviv Res Pract. 2025;19:846\u201370.","journal-title":"J Cancer Surviv Res Pract"},{"key":"1817_CR46","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1111\/jan.14959","volume":"77","author":"W McInally","year":"2021","unstructured":"McInally W, Gray-Brunton C, Chouliara Z, Kyle RG. Life interrupted: experiences of adolescents, young adults and their family living with malignant melanoma. J Adv Nurs. 2021;77:3867\u201379.","journal-title":"J Adv Nurs"},{"key":"1817_CR47","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00520-025-10001-1","volume":"33","author":"R Moore","year":"2025","unstructured":"Moore R, Ahmad N, Kadosh M, et\u00a0al. Identifying gaps and needs in care for adolescents and young adults with melanoma. Support Care Cancer. 2025;33:913.","journal-title":"Support Care Cancer"},{"key":"1817_CR48","first-page":"3356","volume":"28","author":"P Rasic","year":"2023","unstructured":"Rasic P, Jeremic M, Jeremic R, et\u00a0al. Targeting B7-H3-A novel strategy for the design of anticancer agents for extracranial pediatric solid tumors treatment. Mol Basel Switz. 2023;28:3356.","journal-title":"Mol Basel Switz"},{"key":"1817_CR49","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17186","volume":"193","author":"H Rafei","year":"2021","unstructured":"Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2021;193:216\u201330.","journal-title":"Br J Haematol"},{"key":"1817_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drudis.2021.07.007","volume":"27","author":"A Chatterjee","year":"2022","unstructured":"Chatterjee A, Paul S, Bisht B, et\u00a0al. Advances in targeting the WNT\/\u03b2-catenin signaling pathway in cancer. Drug Discov Today. 2022;27:82\u2013101.","journal-title":"Drug Discov Today"},{"key":"1817_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-025-02363-1","volume":"24","author":"X Wu","year":"2025","unstructured":"Wu X, Que H, Li Q, Wei X. Wnt\/\u03b2-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy. Mol Cancer. 2025;24:171.","journal-title":"Mol Cancer"},{"key":"1817_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.soc.2025.01.004","volume":"34","author":"LA Janes","year":"2025","unstructured":"Janes LA, Haykal T, Angeles CV. Vaccines in melanoma: past, present, and future. Surg Oncol Clin N Am. 2025;34:411\u201321.","journal-title":"Surg Oncol Clin N Am"},{"key":"1817_CR53","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.21.02838","volume":"40","author":"DW Parsons","year":"2022","unstructured":"Parsons DW, Janeway KA, Patton DR, et\u00a0al. Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the National Cancer Institute-Children\u2019s Oncology Group pediatric MATCH trial. J Clin Oncol. 2022;40:2224\u201334.","journal-title":"J Clin Oncol"},{"key":"1817_CR54","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1111\/bcp.15119","volume":"88","author":"B Aurich","year":"2022","unstructured":"Aurich B, Apele-Freimane D, Banaschewski T, et\u00a0al. c4c: paediatric pharmacovigilance: methodological considerations in research and development of medicines for children\u2014a c4c expert group white paper. Br J Clin Pharmacol. 2022;88:4997\u20135016.","journal-title":"Br J Clin Pharmacol"},{"key":"1817_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17081342","volume":"17","author":"E Turner","year":"2025","unstructured":"Turner E, Sirrine EH, Crabtree VM, et\u00a0al. An interprofessional approach to developing family psychosocial support programs in a pediatric oncology healthcare setting. Cancers Basel. 2025;17:1342.","journal-title":"Cancers Basel"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01817-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:02:47Z","timestamp":1787245367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01817-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1817"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01817-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following conflicts of interest: Susana Puig declares research grants from Almirall, Pfizer, Regeneron Sanofi, La Roche Posay, Philogen, ISDIN, International School of Derma, and consulting fees from Sanofi, Regeneron, ISDIN, L\u2019Oreal, La Roche Posay, International School of Derma, and personal fees from Sanofi, Sun pharma, Cantabria, Eucerin, ISDIN, L\u2019Oreal, La Roche Posay, Almirall, Avene, Pierre Fabre, and support for attending meetings and\/or travel from Almirall, Cantabria, and ISDIN. Cristina Carrera declares support for attending meetings and\/or travel from ISDIN, BMS, Sanofi, and Pierre Fabre, and educational fees from International School of Derma and La Roche Posay. Pablo Balado-Sim\u00f3 and Marc Hern\u00e1ndez-Santacana declare support for attending meetings and\/or travel from Almirall and La Roche Posay. Miguel Mansilla-Polo has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}